Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Twonko at least we are at similar sp as of 10 years ago loads of permabear 100 companies cant say the same look at the banks bt cna etc etc the ftse is similar to a decade ago where the dow is x4. Blame the system not a solid GB company gla regards jack
well well well Phildon, I understand your frustration and if we look into the time perspective we may observe some very interesting similarities.
TR64 seems to have stopped his trolling on this board with antivax anti GSK clutter of this board; it may be that he was cautioned again by LS as in the past.
However, I spotted a paragraph in Ttonko posts which is almost a carbon copy of TR's "I was buying them for the current price a decade ago and whilst the div has been nice, I would also have expected the SP to keeppace with inflation as an absolute minimum," More than that I checked the history of his posts and the antivax theme is persistent as well.
I will keep a close eye if these 2 themes will develop into a compulsive obsessive manner and if it will be the case than TR is back from his ashes.
Not so. Lockdown has seen people staying at home instead of going out for vaccinations, so vaccine income is reeduced. This may pick up as GP's encourgae vaccination catch-up and as travel increases but who knows. What is more worrying is the long term stagnation of this share. I was buying them for the current price a decade ago and whilst the div has been nice, I would also have expected the SP to keeppace with inflation as an absolute minimum, which it has not done. Covid-19 was another missed opportunity for GSK. I am now looking for the reorganistion as a way to reduce my holding without taking too much of a hit. There are better places for my money. Including better drug Companies,
There is promising news but the shares do seem stuck in a trading range at the moment, and clearly if you can buy them close to £12, invariably you can then sell them for 10% more a few weeks later. GSK needs to break this cycle, which apart from anything else is undervaluing the overall group. The share price should be far higher than this, especially in a pandemic.
Hi P/C Never thought I was such a pessimist esp as GSK is one of my biggest holdings. My ave cost is a fair bit higher, but the SP has dropped since the yr end results were published at end of January. The chart looks a little better now with the bounce off £12. Think we just need to be patient and will eventually be higher. Will be intersting to see how the split works and whther we get two different shares or are asked to buy new shares. At least we still get the 80p p.a divi for next 12 mths, as long as cashflow can support it. Would be nice to get some positive news from Emma, as seems to ignore the impressive investments and JVs that I'm sure would lift the SP. Elliot's involvement created a decent move up for a day or two, but the SP been flat since; around 1350 mark. I will be holding for a good while yet, with first target around £15 to sell one batch (1/3 of my shares) at a profit. GLA - Cheers - CSDI
I am sure the exchange rate has been pegging back the UK SP for some time now. Early last yr the R/E was $1.25 = £1, now it's over $1.40 = £1. This is a major issue for UK holders, as earnings are in $, but then converted to £. As the divi has been barely covered for some time at 80p p.a, the risk increases of a cut before end of year as already signalled. GSK has repeatedly indicated that earnings are down with Covid and we are not out of the woods yet. The movement in exchange rate alone means that UK earnings (EPS) would be about 10% lower than LY if US earnings remained constant. Factor in an expected reduction in earnings (in US $) means a bigger drop in EPS. No wonder the SP has performed poorly since last summer, and then we have the expense of splitting the company which is costing approx £1B over 2-3 yrs. Ummm - I wish the old GSK was still here where we could be confident of SP moving to £16 and back down to £14. GLA - patience required - CSDI
Very true - although if they buy today they won't need to splash out :) looks like the US will open on the cheap.. But the point is well taken... however if the pound strengthens to the dollar, would that not help the US SP move up, in order to gain parity with the LSE SP? TBH I've no idea (my background is in pharma)
Hi Covgaz Yes totally agree. Think I first bought these in 2007 at similar price to now. took 3 yrs to sell as fell in the 2008 crash. divi been settled at 80p p.a for at least 6 yrs now, but facing a cut after this yr end. Normally could buy below £14 and sell around £16, but trapped again since last summer as City not impressed. i'm stcuk holding some as bought at 1612, 1479 and 1388 bw July and Nov last year. Did have 3 more batches but took loss on two to free up some capital and made profit on one batch recently (bought @ 1215 in Feb, sold @ 1354 on elliot day). Good for income as you say, but without growth in the SP can be a tie on capital, and missed opportunity elsewhere. GLA - CSDI .
I remember selling these many years ago because they were a very boring hold. It seems the price is still where i sold them at. I thought this was supposed to be a blockbuster drugs company? It would seem not , but ok to hold for the divi , beats the banks hands down.
GSK did miss the boat, but the AZ vaccine seems to be hitting more setbacks on a weekly basis. I had my first one in March & was bad = I'm not looking forward to the 2nd next month. As long as the board do their job & product demand doesn't fade, GSK should be an excellent long term dividend play. GL & thanks for the reply.
The Loaf, GSK have missed the boat as far as CV19 vaccine is concerned. The SP has been in doldrums for some time, since I bought last July at 1612p. We seeem to be consolidating bw 1325-1350 and forming a support, and with ex-divi date a fortnight away we might see a climb towards £14 which would be a start. The SP will ultimately be driven by the split/restructure, and with a divi reduction coming into '22 I am not sure how the city will take to it. At least with Elliot supposedly involved (although not seen any RNS confirming =>3% stake) this should push the directors to get a grip and create proper value for us suffering PIs. Time will tell, but patience required for sure. Cheers & GL - CSDI
GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - GSK and Vir Biotechnology Inc say the European Medicines Agency has started a rolling review of test results for their Covid-19 treatment sotrovimab. The review is for use in people 12 years and older. A rolling review means the EMA will evaluate the test data on sotrovimab as it becomes available. A formal marketing authorisation application will be made once there is enough supporting evidence. Sotrovimab has not yet been granted marketing authorisation anywhere in the world, though an Emergency Use Authorization application has been submitted to the US Food & Drug Administration.